(Q37723835)

English

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes

scientific article published on 10 January 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes (English)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

0 references

Eva Hellström-Lindberg

5

object named as

Eva Hellström-Lindberg

0 references

Valeria Santini

object named as

Valeria Santini

4

0 references

Guillermo F Sanz

object named as

Guillermo Sanz

7

0 references

2

object named as

Pierre Fenaux

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Norbert Gattermann

6

object named as

Norbert Gattermann

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

8

object named as

Alan F List

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Lewis B Silverman

1

object named as

Lewis R Silverman

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

author name string

Ghulam J Mufti

3

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Eva Hellström-Lindberg

5

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Steven D Gore

9

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

John F Seymour

10

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

language of work or name

0 references

publication date

10 January 2011

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

number of pages

6

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

117

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

12

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

2697-2702

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Allogeneic stem cell transplantation for myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Gene silencing in cancer in association with promoter hypermethylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Multiple new phenotypes induced in and 3T3 cells treated with 5-azacytidine

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

23 August 2017

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

28 September 2017

Improving survival in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

1 September 2018

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

1 September 2018

Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

1 September 2018

Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4000012

1 September 2018

Gemifloxacin for the treatment of respiratory tract infections: in vitro susceptibility, pharmacokinetics and pharmacodynamics, clinical efficacy, and safety

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25774

21 January 2018

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.25774

21 January 2018

Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/21656747

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/CNCR.25774

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

22 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37723835&oldid=2131064854"